drugset / Trial / NCT07139366
Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims at evaluating efficacy and safety of Saccharomyces boulardii combined with bismuth-containing quadruple Therapy versus bismuth-containing quadruple Therapy(bismuth#esomeprazole#tetracycline and furazolidone) in H. pylori rescue therapy. It is hypothesized that Saccharomyces boulardii combined with bismuth-containing quadruple Therapy is superior to bismuth-containing quadruple Therapy. Patients with confirmed failure of H. pylori eradication will be randomized to one of the treatments described above. At week 6 follow-up visits, a urea breath test#rapid urease test or helicobacter pylori stool antigen test will be performed to confirm eradication.
Timeline
- Start
- 2025-10-28
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Saccharomyces Boulardii Oral Powder | Unknown | 500 mg | Oral |
| Background | Bismuth Potassium Citrate | Unknown | 220 mg | Oral |
| Background | Esomeprazole | Small molecule | 20 mg | Oral |
| Background | Furazolidone | Small molecule | 100 mg | Oral |
| Background | Tetracycline | Unknown | 500 mg | Oral |